Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03681561 · ClinicalTrials.gov registry record · Phase 1
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
A Phase 1 study of Hodgkin Lymphoma, sponsored by Veronika Bachanova.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
- 6
- Study locations
NCT03681561: Recruiting Phase 1 study of Hodgkin Lymphoma, sponsored by Veronika Bachanova.
NCT03681561 is a Phase 1 study of Hodgkin Lymphoma that is actively recruiting participants, run by Veronika Bachanova. The registered enrollment target is 54 participants, below the 165-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (67% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03681561, a Phase 1 study of Hodgkin Lymphoma, is actively recruiting participants, sponsored by Veronika Bachanova.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a Phase I/II, multicenter, open-label, dose escalation/dose-expansion study to evaluate the tolerability, safety, and the maximum tolerated dose (MTD) of ruxolitinib when given with fixed dose nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma (cHL).
Primary Outcome
To assess the maximum tolerated dose (MTD) of ruxolitinib in combination with nivolumab in patients with relapsed/refractory Hodgkin lymphoma. (Phase I Only)
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ruxolitinib
Study Locations (6)
Illinois
- University of Illinois Cancer Center - Chicago
Indiana
- Indiana Melvin and Bren Simon Comprehensive Cancer Center - Indianapolis
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Minnesota
- University of Minnesota - Minneapolis
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2018-09-13 |
| Est. Completion | 2027-07 |
| Phase | Phase 1 |
What NCT03681561 shows while recruiting
NCT03681561 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 165-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Hodgkin Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT03681561 lists 6 locations in 6 states (Illinois, Indiana, Iowa).
Frequently Asked Questions
What is clinical trial NCT03681561 about?
NCT03681561 is a clinical study titled "Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma". This is a Phase I/II, multicenter, open-label, dose escalation/dose-expansion study to evaluate the tolerability, safety, and the maximum tolerated dose (MTD) of ruxolitinib when given with fixed dose nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma (cHL).
What is the current status of trial NCT03681561?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2018-09-13. Estimated completion is 2027-07.
What conditions does trial NCT03681561 study?
This clinical trial studies the following conditions: Hodgkin Lymphoma.
What interventions are being tested in trial NCT03681561?
The interventions under investigation include: Nivolumab (DRUG), Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT03681561?
This trial is sponsored by Veronika Bachanova, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03681561 being conducted?
This trial has 6 study locations across Illinois, Indiana, Iowa, Minnesota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03681561's enrollment target sits among peer trials
54 36th of 71 higher than 35 of 71 other Hodgkin Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.
RECRUITING · Phase 1
-
ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells
RECRUITING · Phase 1
-
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
RECRUITING · Phase 1
-
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI